ストックスクリーナーアプリを入手
51.92
0.54%
0.2729
前日終値:
$51.65
開ける：
$52
24時間の取引高:
499.80K
Relative Volume:
0.15
時価総額：
$23.02B
収益：
$2.38B
当期純損益:
$1.32B
株価収益率:
29.16
EPS:
1.7806
ネットキャッシュフロー:
$897.24M
1週間 パフォーマンス:
+2.95%
1か月 パフォーマンス:
+8.41%
6か月 パフォーマンス:
+31.17%
1年 パフォーマンス:
+55.71%
1日の値動き範囲:
$51.34
$52.14
1週間の範囲:
$49.28
$52.14
52週間の値動き範囲:
$32.15
$52.14
Royalty Pharma Plc Stock (RPRX) Company Profile
名前
Royalty Pharma Plc
セクター
電話
(212) 883-0200
住所
110 EAST 59TH STREET, NEW YORK, NY
Compare RPRX vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
RPRX
Royalty Pharma Plc
|
51.93 | 22.90B | 2.38B | 1.32B | 897.24M | 1.7806 |
VRTX
Vertex Pharmaceuticals Inc
|
451.86 | 110.45B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
721.55 | 74.73B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
818.49 | 50.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.35 | 38.03B | 4.29B | 577.22M | 641.34M | 4.2086 |
ONC
Beone Medicines Ltd Adr
|
314.01 | 32.24B | 5.36B | 287.73M | 924.18M | 2.5229 |
Royalty Pharma Plc Stock (RPRX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-01-30 | アップグレード | UBS | Neutral → Buy |
| 2025-09-30 | 開始されました | Goldman | Buy |
| 2025-05-16 | 開始されました | Morgan Stanley | Overweight |
| 2024-06-03 | ダウングレード | UBS | Buy → Neutral |
| 2022-06-14 | 再開されました | UBS | Buy |
| 2022-05-13 | 開始されました | Scotiabank | Sector Outperform |
| 2022-04-27 | 開始されました | Goldman | Buy |
| 2022-04-14 | アップグレード | JP Morgan | Neutral → Overweight |
| 2022-04-06 | 再開されました | Morgan Stanley | Overweight |
| 2021-10-29 | アップグレード | Citigroup | Neutral → Buy |
| 2021-07-30 | 開始されました | Tigress Financial | Buy |
| 2020-11-09 | アップグレード | UBS | Neutral → Buy |
| 2020-07-14 | 開始されました | Evercore ISI | In-line |
| 2020-07-13 | 開始されました | BofA Securities | Buy |
| 2020-07-13 | 開始されました | Citigroup | Neutral |
| 2020-07-13 | 開始されました | Cowen | Outperform |
| 2020-07-13 | 開始されました | Goldman | Neutral |
| 2020-07-13 | 開始されました | JP Morgan | Neutral |
| 2020-07-13 | 開始されました | Morgan Stanley | Equal-Weight |
| 2020-07-13 | 開始されました | SunTrust | Buy |
| 2020-07-13 | 開始されました | UBS | Neutral |
すべてを表示
Royalty Pharma Plc (RPRX) 最新ニュース
Royalty pharma – funding the next generation of medicines - Livewire Markets
RPRX SEC FilingsRoyalty Pharma Plc 10-K, 10-Q, 8-K Forms - Stock Titan
Income Investors Should Know That Royalty Pharma plc (NASDAQ:RPRX) Goes Ex-Dividend Soon - Yahoo Finance
Hosking Partners LLP Purchases 155,450 Shares of Royalty Pharma PLC $RPRX - MarketBeat
Mitsubishi UFJ Asset Management Co. Ltd. Grows Stock Position in Royalty Pharma PLC $RPRX - MarketBeat
C WorldWide Group Holding A S Has $27.07 Million Stake in Royalty Pharma PLC $RPRX - MarketBeat
Accelerated Royalty Deals and Dividend Hike Could Be A Game Changer For Royalty Pharma (RPRX) - simplywall.st
MSN Money - msn.com
Royalty Pharma (NASDAQ:RPRX) Upgraded at Wall Street Zen - MarketBeat
Royalty Pharma (NASDAQ:RPRX) Releases Earnings Results, Beats Estimates By $0.08 EPS - MarketBeat
[Form 4] Royalty Pharma plc Insider Trading Activity - Stock Titan
Christopher Hite gains 24,263 Royalty Pharma (RPRX) shares via equity award - Stock Titan
Royalty Pharma (RPRX) EVP gets 18,197-share equity award - Stock Titan
10% Of This Royalty Pharma Insider's Holdings Were Sold - Yahoo Finance
Royalty Pharma raises 2026 portfolio receipts guidance to $3.325B-$3.45B as it scales R&D co-funding - msn.com
Royalty Pharma to Present at Upcoming Investor Conferences - Moomoo
Citigroup Raises Royalty Pharma (NASDAQ:RPRX) Price Target to $66.00 - MarketBeat
Royalty Pharma schedules two May healthcare conference webcasts - Stock Titan
JPMorgan Chase & Co. Issues Positive Forecast for Royalty Pharma (NASDAQ:RPRX) Stock Price - MarketBeat
Denali Therapeutics (NASDAQ: DNLI) adds cash on AVLAYAH deal despite Q1 loss - Stock Titan
Royalty Pharma Reports Q1 2026 Results: Full Earnings Call Transcript - Sahm
Theravance Biopharma (NASDAQ: TBPH) slashes R&D after ampreloxetine trial miss - Stock Titan
Vanguard Group Inc. Cuts Stake in Royalty Pharma PLC $RPRX - MarketBeat
Royalty Pharma plc (NASDAQ:RPRX) Q1 2026 Earnings Call Transcript - Insider Monkey
Royalty Pharma Q1 2026 slides: double-digit growth, guidance raised By Investing.com - Investing.com Australia
Royalty Pharma Earnings: Strong Cash Flows and New Deals Support Positive Outlook and Key Readouts - Morningstar
Royalty Pharma (RPRX) Margin Drop To 33.9% Tests Bullish Growth Narrative In Q1 2026 - Sahm
Improved Growth Outlook Prompts Fair Value Estimate Increase for Narrow-Moat Royalty Pharma - Morningstar
Royalty Pharma’s Earnings Call Signals Confident Growth - TipRanks
Royalty Pharma Q1 Earnings Call Highlights - MarketBeat
Royalty Pharma plc Q1 2026 Financial Results: Earnings, Revenue, and Risk Factors from Latest 10-Q Filing - Minichart
Royalty Pharma Q1 2026 earnings preview - msn.com
Royalty Pharma plc Q1 2026 Earnings Call Summary - Yahoo Finance
Earnings call transcript: Royalty Pharma Q1 2026 shows robust growth By Investing.com - Investing.com India
Royalty Pharma (RPRX) Q1 2026 Earnings Transcript - AOL.com
Royalty Pharma Reports 10% Growth in Portfolio Receipts for Q1 2026 Driven by Strong Product Performance - Minichart
RPRX vs. AMGN: Which Stock Is the Better Value Option? - Yahoo! Finance Canada
Royalty Pharma Q1 2026 slides: double-digit growth, guidance raised - Investing.com
Royalty Pharma PLC reports results for the quarter ended March 31Earnings Summary - TradingView
Royalty Pharma plc Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Royalty Pharma (RPRX) Valuation Check As Q1 Earnings Expectations Drive Strong Share Price Momentum - Sahm
RPRX Stock Price Prediction 2025-2026 | Royalty Pharma Plc Forecast | 24/7 Wall St. - 24/7 Wall St.
Earnings call transcript: Royalty Pharma Q1 2026 shows robust growth - Investing.com
Royalty Pharma PLC (RPRX) Hit a 52 Week High, Can the Run Continue? - Yahoo Finance
Royalty Pharma plc 1Q 2026: Revenue $630.58M, EPS $0.67— 10-Q Summary - TradingView
Royalty Pharma (RPRX) Q1 Earnings and Revenues Surpass Estimates - Yahoo Finance
Tranche Update on Royalty Pharma plc's Equity Buyback Plan announced on January 10, 2025. - marketscreener.com
Royalty Pharma (NASDAQ: RPRX) grows Q1 2026 profit and cash flow - Stock Titan
Royalty Pharma plc 2026 Q1ResultsEarnings Call Presentation (NASDAQ:RPRX) 2026-05-06 - Seeking Alpha
Earnings Flash (RPRX) Royalty Pharma plc Reports Q1 Revenue $631.0M - marketscreener.com
Royalty Pharma : Q1 2026 Financial Results Presentation - marketscreener.com
Royalty Pharma Plc (RPRX) 財務データ
収益
当期純利益
現金流量
EPS
4.20%
3.26%
大文字化:
|
ボリューム (24 時間):